首页> 美国卫生研究院文献>BMC Pediatrics >A multicentre randomised controlled trial of levetiracetam versus phenytoin for convulsive status epilepticus in children (protocol): Convulsive Status Epilepticus Paediatric Trial (ConSEPT) - a PREDICT study
【2h】

A multicentre randomised controlled trial of levetiracetam versus phenytoin for convulsive status epilepticus in children (protocol): Convulsive Status Epilepticus Paediatric Trial (ConSEPT) - a PREDICT study

机译:左乙拉西坦与苯妥英钠治疗儿童惊厥性癫痫持续状态的多中心随机对照试验(协议):惊厥性癫痫持续状态小儿试验(ConSEPT)-PREDICT研究

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundConvulsive status epilepticus (CSE) is the most common life-threatening childhood neurological emergency. Despite this, there is a lack of high quality evidence supporting medication use after first line benzodiazepines, with current treatment protocols based solely on non-experimental evidence and expert opinion. The current standard of care, phenytoin, is only 60% effective, and associated with considerable adverse effects. A newer anti-convulsant, levetiracetam, can be given faster, is potentially more efficacious, with a more tolerable side effect profile. The primary aim of the study presented in this protocol is to determine whether intravenous (IV) levetiracetam or IV phenytoin is the better second line treatment for the emergency management of CSE in children.
机译:背景惊厥性癫痫持续状态(CSE)是最常见的威胁生命的儿童神经系统紧急情况。尽管如此,仍然缺乏高质量的证据支持在一线苯二氮卓类药物治疗后的药物使用,目前的治疗方案仅基于非实验证据和专家意见。苯妥英钠目前的治疗标准只有60%有效,并伴有相当大的不良反应。新型抗惊厥药左乙拉西坦可以更快地给药,可能更有效,且副作用更可耐受。本方案中进行的研究的主要目的是确定静脉内(IV)左乙拉西坦或IV苯妥英钠是否是儿童CSE紧急处理的更好的二线治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号